【New Delhi】Swiss drug major Novartis' multi-billion-dollar overhaul through deals with two multinational firms — GlaxoSmithKline (GSK) and Eli Lilly — is likely to have an impact on the Indian market, too, as all the three companies have significant presence in the country, primarily in the segments involved in the transaction.
On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion. Besides, Novartis will pay up to $1.5 billion more if certain milestones are met. It will also form a consumer health joint venture, in which GSK, with an equity interest of 63.5 per cent, will have majority control. Novartis has also agreed to sell its animal health arm to Eli Lilly for about $5.4 billion.
○Pfizer, AstraZeneca shares climb up amidst deal talks
【MUMBAI】Shares of the Indian subsidiaries of Pfizer and AstraZeneca ruled strong for the second successive day, after reports of a possible acquisition of AstraZeneca by Pfizer did the rounds.
UK's Sunday Times had reported that Pfizer had made a $100-billion offer to take over AstraZeneca, which, in the last few years, has been struggling to register profits owing to the patent expiry of many of its blockbuster drugs.
The two drugmakers declined to confirm the development, even as the news sent market punters to bet on the likely impact on its Indian subsidiaries. While the shares of AstraZeneca gained 5.3% in two days to end Tuesday's trading at Rs 1109.80 a share, Pfizer gained 5% during the period to end at 1294.55 a share on Tuesday.
【News source】
Novartis-GSK-Eli Lilly deal may affect Indian market
GlaxoSmithKline swaps oncology for vaccines with Novartis AG
Pharma giants Novartis, GSK swap assets in $23-b deal
Pfizer, AstraZeneca shares climb up amidst deal talks
Your Comments